Friday, 16 October 2026European Markets

HAFNIA LIMITED Stock Is 27% Up In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of HAFNIA LIMITED (Oslo Børs Benchmark Index_GI: HAFNI.OL) rose by a staggering 27.84% in 21 sessions from kr49.75 to kr63.60 at 19:39 EST on Thursday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is jumping 1.3% to kr1,235.65, after two successive sessions in a row of losses.

HAFNIA LIMITED's last close was kr63.10, 1.56% under its 52-week high of kr64.10.

About HAFNIA LIMITED

Hafnia Limited owns and operates oil product tankers. The company operates through four segments: Long Range II (LR2), Long Range I (LR1), Medium Range (MR), and Handy size (Handy). It transports petroleum oil products, vegetable oil, and easy chemicals to national and international oil companies, and chemical companies, as well as trading and utility companies. The company provides ship owning, ship-management, chartering, investment, and agency office services. As of March 29, 2022, it operated a fleet of 237 vessels, including newbuilds, of which 145 are owned or chartered-in, including 10 owned LR2s, 40 owned and chartered-in LR1s, 58 owned and chartered-in MRs, and 29 owned Handy and eight stainless steel 25K vessels. The company is based in Hamilton, Bermuda. Hafnia Limited is a subsidiary of BW Group Limited.

PE Ratio

HAFNIA LIMITED has a trailing twelve months price to earnings ratio of 6.64. Meaning, the purchaser of the share is investing kr6.64 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 31.8%.

More news about HAFNIA LIMITED (HAFNI.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com